Home › Compound Library › PT-141 (Bremelanotide)

PT-141 (Bremelanotide)

Peptideprescriptionsubcutaneous · inferred

Melanocortin receptor agonist (MC3R/MC4R) FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Metabolite of melanotan II with elimination half-life of 2.7 hours. 100% SC bioavailability, 21% protein binding. Administered as single 1.75 mg SC dose at least 45 min before anticipated sexual activity. Max 1 dose per 24 hours.

Projected serum levels — 1.8 mg, as needed (shown daily)

PT-141 (Bremelanotide)
PT-141 (Bremelanotide) modeled serum levels, 1.8 mg as needed (shown daily) over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 1.8 mg as needed (shown daily) (subcutaneous).

Modeled steady state after ~1 days: peak ≈ 0.70 mg, trough ≈ 0.002 mg body load. Population-based estimate over 15 days for a 1.8 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Peptide
Route modeled
Subcutaneous
Model confidence
inferred
Half-life
2.7 h
Common dose
1.8 mg
Suggested maximum
1.8 mg/day
Reference dose range
0.88–1.8 mg (single dose)
Suggested cadence
as needed (shown daily)
Validated against
1.8 mg sc — Cmax 0.073 mg/L at 1 h

Documented interactions

  • danger
    Melanotan II + PT-141 (Bremelanotide) Stacked effects

    Melanotan II and PT-141 (Bremelanotide) both push the mc1r, mc3r, mc4r, and mc5r in the same direction.

  • moderate
    KPV (Lys-Pro-Val) + PT-141 (Bremelanotide) Stacked effects

    KPV (Lys-Pro-Val) and PT-141 (Bremelanotide) both push the mc1r and mc3r in the same direction.

  • watch
    Semax + PT-141 (Bremelanotide) Stacked effects

    PT-141 (Bremelanotide) and Semax both push the mc4r in the same direction.

Serum checks 3 modeled interaction pairings for pt-141 (bremelanotide) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Bremelanotide for Treatment of Female Hypoactive Sexual Desire Kingsberg SA et al. · Obstetrics & Gynecology, 2019 DOI

    Pivotal phase 3 RECONNECT trials demonstrating bremelanotide 1.75 mg SC significantly increased sexual desire and reduced distress associated with low sexual desire in premenopausal women.

  2. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study Diamond LE et al. · Journal of Urology, 2008 DOI

    RCT showing bremelanotide rescued erectile function in 40% of men who failed sildenafil, confirming a central melanocortin-mediated mechanism distinct from PDE5 inhibition.

  3. Phase I randomized placebo-controlled, double-blind study of the safety and tolerability of bremelanotide coadministered with ethanol Pfaus JG et al. · Clinical Therapeutics, 2017 DOI

    Phase I drug interaction study confirming no clinically significant PK interactions between bremelanotide and ethanol, with no additional safety concerns in the combination.

3 published studies referenced in the app, each with a plain-language summary.